Indication
NTRK Fusion Positive Solid Tumors
5 clinical trials
4 products
Clinical trial
A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects With Previously Treated NTRK Fusion CancersStatus: Completed, Estimated PCD: 2022-04-11
Product
SelitrectinibClinical trial
A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK FusionStatus: Active (not recruiting), Estimated PCD: 2025-07-20
Product
BAY2757556Product
LarotrectinibClinical trial
A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-25
Clinical trial
Comparative Effectiveness Study of Real-world Control of TRK Fusion Positive Cancer With Patients From Larotrectinib (Vitrakvi) Clinical TrialsStatus: Completed, Estimated PCD: 2023-08-31
Product
Other treatmentsClinical trial
A Phase 1 Study of the Oral TRK Inhibitor Larotrectinib in Adult Patients With Solid TumorsStatus: Completed, Estimated PCD: 2017-02-01